Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies
暂无分享，去创建一个
Z. Estrov | T. Kadia | G. Borthakur | E. Jabbour | N. Daver | C. Dinardo | M. Keating | S. O'brien | J. Burger | N. Jain | C. Peterson | J. Jorgensen | W. Wierda | A. Ferrajoli | P. Strati | P. Thompson